Subtopic Deep Dive
Acetylcholine Receptor Antibodies in Myasthenia Gravis
Research Guide
What is Acetylcholine Receptor Antibodies in Myasthenia Gravis?
Acetylcholine receptor antibodies (AChR-Abs) are autoantibodies targeting nicotinic acetylcholine receptors at the neuromuscular junction, present in 80-87% of myasthenia gravis patients and central to its autoimmune pathogenesis.
Lindstrom et al. (1976) first detected elevated AChR-Abs in 87% of 71 myasthenia gravis sera using radioimmunoprecipitation assays, absent in 175 controls (1175 citations). These IgG antibodies block receptor function, reduce receptor density, and correlate with disease severity (Conti-Fine et al., 2006). Over 10 key papers since 1976 detail their detection, epitopes, and therapeutic targeting.
Why It Matters
AChR-Abs detection enables precise diagnosis in the majority MG subgroup, guiding therapies like eculizumab, which improved outcomes in refractory AChR-positive generalized MG (Howard et al., 2017, 737 citations). Thymectomy benefits AChR-Ab positive nonthymomatous patients, reducing antibody levels and symptoms over 3 years (Wolfe et al., 2016, 869 citations). Targeted immunotherapies modulating AChR-Abs reduce hospitalization rates and improve quality of life, as per international consensus (Narayanaswami et al., 2020).
Key Research Challenges
Seronegative MG Diagnosis
15-20% generalized MG patients lack detectable AChR-Abs by standard assays, complicating diagnosis (Leite et al., 2008, 505 citations). Low-affinity IgG1 antibodies require cell-based assays for detection. This delays treatment in seronegative cases mimicking AChR-positive disease.
Antibody-Therapy Correlation
AChR-Ab titers correlate imperfectly with clinical severity and treatment response, limiting monitoring (Conti-Fine et al., 2006). Factors like epitope specificity influence pathogenicity. Quantifying functional antibody impact remains challenging.
Epitope Mapping Precision
Mapping pathogenic AChR epitopes for vaccine or tolerogen design faces structural complexity (Lindstrom et al., 1976). Multiple epitopes on alpha subunits vary by patient. High-resolution techniques are needed for targeted therapies.
Essential Papers
Antibody to acetylcholine receptor in myasthenia gravis
Jon Lindstrom, Marjorie E. Seybold, Vanda A. Lennon et al. · 1976 · Neurology · 1.2K citations
Elevated amounts of antibodies specific for acetylcholine receptors were detected in 87 percent of sera from 71 patients with myasthenia gravis but not in 175 sera from individuals without myasthen...
Auto-antibodies to the receptor tyrosine kinase MuSK in patients with myasthenia gravis without acetylcholine receptor antibodies
Werner Hoch, John McConville, Sigrun Helms et al. · 2001 · Nature Medicine · 1.2K citations
Randomized Trial of Thymectomy in Myasthenia Gravis
Gil I. Wolfe, Henry J. Kaminski, Inmaculada Aban et al. · 2016 · New England Journal of Medicine · 869 citations
Thymectomy improved clinical outcomes over a 3-year period in patients with nonthymomatous myasthenia gravis. (Funded by the National Institute of Neurological Disorders and Stroke and others; MGTX...
Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study
James F. Howard, Kimiaki Utsugisawa, Michael Benatar et al. · 2017 · The Lancet Neurology · 737 citations
A systematic review of population based epidemiological studies in Myasthenia Gravis
Aisling Carr, Chris R. Cardwell, Peter O McCarron et al. · 2010 · BMC Neurology · 732 citations
We report marked variation in observed frequencies of MG. We show evidence of increasing frequency of MG with year of study and improved study quality. This probably reflects improved case ascertai...
Myasthenia gravis: past, present, and future
Bianca M. Conti‐Fine, Monica Milani, Henry J. Kaminski · 2006 · Journal of Clinical Investigation · 673 citations
Myasthenia gravis (MG) is an autoimmune syndrome caused by the failure of neuromuscular transmission, which results from the binding of autoantibodies to proteins involved in signaling at the neuro...
International Consensus Guidance for Management of Myasthenia Gravis
Pushpa Narayanaswami, Donald B. Sanders, Gil I. Wolfe et al. · 2020 · Neurology · 652 citations
This updated formal consensus guidance of international MG experts, based on new evidence, provides recommendations to clinicians caring for patients with MG worldwide.
Reading Guide
Foundational Papers
Start with Lindstrom et al. (1976) for AChR-Ab discovery and assay validation (1175 citations), then Conti-Fine et al. (2006) for pathogenesis mechanisms linking antibodies to neuromuscular failure.
Recent Advances
Study Howard et al. (2017) for eculizumab in refractory AChR-MG and Narayanaswami et al. (2020) consensus on management incorporating Ab testing.
Core Methods
Core techniques: radioimmunoprecipitation for Ab quantification (Lindstrom 1976), cell-based assays for seronegative cases (Leite 2008), titer monitoring for therapy response.
How PapersFlow Helps You Research Acetylcholine Receptor Antibodies in Myasthenia Gravis
Discover & Search
Research Agent uses searchPapers('Acetylcholine Receptor Antibodies Myasthenia Gravis') to retrieve Lindstrom et al. (1976, 1175 citations), then citationGraph reveals forward citations like Howard et al. (2017) on eculizumab, while findSimilarPapers expands to epitope studies and exaSearch uncovers recent assays beyond OpenAlex.
Analyze & Verify
Analysis Agent applies readPaperContent on Leite et al. (2008) to extract IgG1 detection methods, verifyResponse with CoVe cross-checks prevalence claims against Conti-Fine et al. (2006), and runPythonAnalysis plots antibody titer correlations from extracted data using pandas, with GRADE grading for evidence quality in diagnostic assays.
Synthesize & Write
Synthesis Agent detects gaps in seronegative MG therapies via contradiction flagging across papers, while Writing Agent uses latexEditText for manuscript sections, latexSyncCitations to link Lindstrom (1976), and latexCompile for figures; exportMermaid visualizes antibody pathogenesis pathways.
Use Cases
"Plot correlation between AChR-Ab titers and MG severity scores from key studies"
Research Agent → searchPapers → Analysis Agent → runPythonAnalysis (pandas scatterplot from Lindstrom 1976/Conti-Fine 2006 data) → matplotlib figure of titer-severity trends with p-values.
"Draft LaTeX review section on AChR-Ab detection assays with citations"
Synthesis Agent → gap detection → Writing Agent → latexEditText('intro') → latexSyncCitations(Lindstrom 1976, Leite 2008) → latexCompile → PDF section ready for submission.
"Find code for AChR antibody binding simulations in MG papers"
Research Agent → paperExtractUrls → Code Discovery → paperFindGithubRepo → githubRepoInspect → verified simulation scripts for epitope modeling from related neuromuscular repos.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers(50+ AChR-MG papers) → citationGraph → GRADE-graded report on antibody prevalence trends. DeepScan applies 7-step analysis with CoVe checkpoints to verify Howard et al. (2017) eculizumab efficacy claims against Lindstrom (1976). Theorizer generates hypotheses on epitope-specific therapies from Conti-Fine (2006) pathogenesis data.
Frequently Asked Questions
What defines AChR antibodies in myasthenia gravis?
AChR antibodies are IgG autoantibodies binding nicotinic acetylcholine receptors, detected in 87% of MG patients via radioimmunoprecipitation (Lindstrom et al., 1976).
What are main detection methods for AChR-Abs?
Standard radioimmunoprecipitation assays detect high-affinity antibodies; cell-based assays identify low-affinity IgG1 in seronegative MG (Leite et al., 2008).
What are key papers on AChR-Abs?
Lindstrom et al. (1976, 1175 citations) discovered AChR-Abs; Conti-Fine et al. (2006) detailed pathogenesis; Howard et al. (2017) showed eculizumab efficacy.
What open problems exist in AChR-Ab research?
Challenges include imperfect titer-severity correlation, seronegative diagnosis, and epitope-specific therapies (Conti-Fine et al., 2006; Leite et al., 2008).
Research Myasthenia Gravis and Thymoma with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Acetylcholine Receptor Antibodies in Myasthenia Gravis with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Myasthenia Gravis and Thymoma Research Guide